Phase 2 RCT | Baxdrostat for treatment-resistant hypertension

Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: A Study of CIN-107 in Adults With Treatment-Resistant Hypertension – BrigHTN – American College of Cardiology

Commentary on Twitter (thread – click for more)

Aldosterone has long been a pharmacologic target for the treatment of hypertension. However, a new small-molecule drug called baxdrostat inhibits aldosterone synthase in patients with treatment-resistant hypertension. 1/14 pic.twitter.com/F27WE4Wa1d

— NEJM (@NEJM) February 3, 2023